{
    "programid": "9001",
    "start": [
        {
            "id": "question1"
        }
    ],
    "manifest": [
        {
            "pages": [
                "main",
                "question1",
                "page1",
                "response1",
				"question2",
                "page2",
				"response2",
				"question3",
                "page3",
				"response3",
                "finalstep"
            ]
        }
    ],
    "topnav": [
        {
            "next-control": "Next",
            "headline": "<p>Meaningful Efficacy Across Multiple Endpoints</p>"
        }
    ],
    "footer": [
        {
            "col-1": {
                "txt": "Privacy",
                "link": "tpl/privacy.html"
            },
            "col-2": {
                "txt": "Feedback",
                "link": "tpl/feedback.html"
            },
            "col-3": {
                "txt": "Get Certificate&nbsp;&#62;",
                "link": "#finalstep"
            },
            "col-4": {
                "txt": "CME Info",
                "link": "tpl/cmeinfo.html"
            },
            "isi": { 
				"txt": "<b>INDICATION</b><br><p>Brandogesic® is indicated for the management of moderate to severe chronic pain when analgesia is needed for an extended period of time.</p><b>CONTRAINDICATIONS</b><br><p>Brandogesic® is contraindicated in patients with a known hypersensitivity to muenkephalin or any of the ingredients of Brandogesic®.</p><p>Brandogesic® is contraindicated in patients with respiratory depression (unless monitored in a setting with resuscitative equipment), asthma, head injury or ileus.</p><p>Brandogesic® is not indicated for pain in the pre- or post-operative period.</p><b>WARNINGS</b><br><p>Respiratory depression that does not respond to hypercapnia is the most significant risk associated with Brandogesic®. Brandogesic® should be administered cautiously to patients with conditions accompanied by hypercapnia, hypoxia or impaired respiratory reserve.</p><p>Many medications, including alcohol, other analgesics or anesthetics, tranquilizers and sedatives, or other CNS depressants can potentiate the effects of Brandogesic®, resulting in respiratory or circulatory collapse, coma or death.</p><p>In the presence of closed head injury, the hypercapnic effects of Brandogesic® may elevate intracranial pressure.</p><p>Brandogesic® may exacerbate gastrointestinal obstruction, particularly in the setting of ileus.</p><p>Brandogesic® may cause spasm at the Sphincter of Oddi.</p><p>Brandogesic® is not recommended for women who are or may become pregnant, during labor and delivery, or while nursing.</p><p>Patients should not perform activities such as driving a car or operating machinery until they understand the effects of Brandogesic® on mental and physical abilities.</p><b>ADVERSE REACTIONS</b><br><p>Adverse reactions reported at (≥5%) in placebo-controlled trials were: sedation and somnolence or insomnia, nausea and/or vomiting, constipation or diarrhea, dizziness, pruritus and headache.</p><p>Dizziness, somnolence and confusion were seen more frequently in patients 65 years of age and over.</p>",
		"link": ""		
		}
	}],
    "sitecontent": [
        {
            "id": "main",
            "template": "Main",
            "title": "PeerPlay: Barndogesic",
            "headline": "From Research to Clinical Practice: What’s New in the Treatment of Cystic Fibrosis?",
            "header": "Select your Specialty",
            "listviewer": [
                "Pulmonology",
                "Other"
            ],
            "audio_url": "",
            "audio_autoplay": ""
        },
        {
            "id": "question1",
            "groupid": "999",
            "template": "Question",
            "title": "PeerPlay: Barndogesic",
            "headline": "<p>QUESTION</p>",
            "question": "Rank what your PNH patients symptoms from most to least-frequent",
            "qid": "q1",
            "type": "single",
            "async-answer": "false",
			"skip": "true",
            "answers": [
                {
                    "answersid": "1",
                    "answerstxt": "<p>Abdominal pain</p>"
                },
                {
                    "answersid": "2",
                    "answerstxt": "<p>Difficulty swallowing</p>"
                },
                {
                    "answersid": "3",
                    "answerstxt": "<p>Smooth muscle spasm</p>"
                },
                {
                    "answersid": "4",
                    "answerstxt": "<p>Thrombosis</p>"
                },
                {
                    "answersid": "5",
                    "answerstxt": "<p>Pain while urinating</p>"
                }
            ],
            "audio_url": "http://c.pro-c.me/programs/demo/audio/bell.mp3",
            "audio_autoplay": "true"
        },
        {
            "id": "response1",
            "groupid": "999",
            "template": "Result",
            "title": "PeerPlay: Barndogesic",
            "headline": "<p>RESULTS</p>",
            "question": "Rank what your PNH patients symptoms from most to least-frequent",
            "qid": "q1r",
            "type": "single",
            "async-answer": "false",
			"skip": "true",
            "answers": [
                {
                    "answersid": "1",
                    "answerstxt": "<p>Abdominal pain</p>",
					"score":"3.5"
                },
                {
                    "answersid": "2",
                    "answerstxt": "<p>Difficulty swallowing</p>",
					"score":"1.75"
                },
                {
                    "answersid": "3",
                    "answerstxt": "<p>Smooth muscle spasm</p>",
					"score":"4.0"
                },
                {
                    "answersid": "4",
                    "answerstxt": "<p>Thrombosis</p>",
					"score":"2.2"
                },
                {
                    "answersid": "5",
                    "answerstxt": "<p>Pain while urinating</p>",
					"score":"1.5"
                }
            ],
            "audio_url": "http://c.pro-c.me/programs/demo/audio/applause.mp3",
            "audio_autoplay": "true"
        },
		 {
            "id": "question2",
            "groupid": "999",
            "template": "Question",
            "title": "PeerPlay: Barndogesic",
            "headline": "<p>QUESTION</p>",
            "question": "What concerns your colleagues most about treating PNH?",
            "qid": "q2",
            "type": "single",
            "async-answer": "false",
			"skip": "true",
            "answers": [
                {
                    "answersid": "c1",
                    "answerstxt": "<p>Blood transfusion risks</p>"
                },
                {
                    "answersid": "c2",
                    "answerstxt": "<p>Cost of treatment</p>"
                },
                {
                    "answersid": "c3",
                    "answerstxt": "<p>CVT risk</p>"
                },
                {
                    "answersid": "c4",
                    "answerstxt": "<p>Budd-Chiari syndrome</p>"
                },
                {
                    "answersid": "c5",
                    "answerstxt": "<p>Pulmonary embolism</p>"
                }
            ],
            "audio_url": "http://c.pro-c.me/programs/demo/audio/bell.mp3",
            "audio_autoplay": "true"
        },
        {
            "id": "response2",
            "groupid": "999",
            "template": "Result",
            "title": "PeerPlay: Barndogesic",
           "headline": "<p>RESULTS</p>",
            "question": "What concerns your colleagues most about treating PNH?",
            "qid": "q2r",
            "type": "single",
            "async-answer": "false",
			"skip": "true",
            "answers": [
                {
                    "answersid": "c1",
                    "answerstxt": "<p>Blood transfusion risks</p>"
                },
                {
                    "answersid": "c2",
                    "answerstxt": "<p>Cost of treatment</p>"
                },
                {
                    "answersid": "c3",
                    "answerstxt": "<p>CVT risk</p>"
                },
                {
                    "answersid": "c4",
                    "answerstxt": "<p>Budd-Chiari syndrome</p>"
                },
                {
                    "answersid": "c5",
                    "answerstxt": "<p>Pulmonary embolism</p>"
                }
            ],
            "audio_url": "http://c.pro-c.me/programs/demo/audio/applause.mp3",
            "audio_autoplay": "true"
        },
		{
            "id": "question3",
            "groupid": "999",
            "template": "Question",
            "title": "PeerPlay: Barndogesic",
            "headline": "<p>QUESTION</p>",
            "question": "Which of the following are involved in accelerating hemolytic anemia?",
            "qid": "q3",
            "type": "single",
            "async-answer": "false",
			"skip": "true",
            "answers": [
                {
                    "answersid": "c1",
                    "answerstxt": "<p>PIGA enzyme</p>"
                },
                {
                    "answersid": "c2",
                    "answerstxt": "<p>Nitric oxide</p>"
                },
                {
                    "answersid": "c3",
                    "answerstxt": "<p>Carbon dioxide</p>"
                },
                {
                    "answersid": "c4",
                    "answerstxt": "<p>C3-convertase</p>"
                },
                {
                    "answersid": "c5",
                    "answerstxt": "<p>DAF/CD55</p>"
                }
            ],
            "audio_url": "http://c.pro-c.me/programs/demo/audio/bell.mp3",
            "audio_autoplay": "true"
        },
        {
            "id": "response3",
            "groupid": "999",
            "template": "Result",
            "title": "PeerPlay: Barndogesic",
           "headline": "<p>RESULTS:</p>",
            "question": "Which of the following are involved in accelerating hemolytic anemia?",
            "qid": "q3r",
            "type": "single",
            "async-answer": "false",
			"skip": "true",
            "answers": [
                {
                    "answersid": "c1",
                    "answerstxt": "<p>PIGA enzyme</p>"
                },
                {
                    "answersid": "c2",
                    "answerstxt": "<p>Nitric oxide</p>"
                },
                {
                    "answersid": "c3",
                    "answerstxt": "<p>Carbon dioxide</p>"
                },
                {
                    "answersid": "c4",
                    "answerstxt": "<p>C3-convertase</p>"
                },
                {
                    "answersid": "c5",
                    "answerstxt": "<p>DAF/CD55</p>"
                }
            ],
            "audio_url": "http://c.pro-c.me/programs/demo/audio/applause.mp3",
            "audio_autoplay": "true"
        },
        {
            "id": "page1",
            "template": "Content",
            "title": "PeerPlay: Barndogesic",
            "headline": "Meaningful Efficacy Across Multiple Endpoints",
            "header": "Meaningful Efficacy Across Multiple Endpoints",
            "listcontent": [
                {
                    "content": "",
                    "image": "program/demo1_assets/chart1.png"
                },
				{
                    "content": "Reduction versus placebo in reported symptoms<sup>1,2</sup>Reduction versus placebo in average number of blood transfusions<sup>1,3,4</sup></h2><div><p><sup>1</sup>2-year, randomized, double-blind, placebo-controlled study in 201 patients with Paroxysmal nocturnal hemoglobulinuria (PNH).  <i>N</i>= 201 patients.<p><sup>2</sup>Symptoms were thrombosis, smooth muscle spasm, difficulty swallowing, and pain while urinating.  Patients had not experienced thrombosis in 6 months prior to trial start.<p><sup>3</sup>Patients had not received blood transfusion in 6 months prior to trial start.<p><sup>4</sup>All patients DAT<sup>-</sup>, total bilirubin > 1.9 mg/dL, lactate dehydrogenase > 330 IU/L at baseline, with follow-up measurements at 2, 4, 8, 12, and 24 months.",
                    "image": "program/demo1_assets/chart2.png"
                }
            ],
            "audio_url": "",
            "audio_autoplay": ""
        },
        {
            "id": "page2",
            "template": "Content",
            "title": "PeerPlay: Barndogesic",
            "headline": "Meaningful Efficacy Across Multiple Endpoints",
            "header": "Meaningful Efficacy Across Multiple Endpoints",
            "listcontent": [
                {
                    "content": "<p><b>Respiratory depression that does not respond to hypercapnia is the most significant risk associated with Brandogesic®. Brandogesic® should be administered cautiously to patients with conditions accompanied by hypercapnia, hypoxia or impaired respiratory reserve.</b></p><h1>In a 2-year RCT of Brandogesic, 2.5% of patients experienced respiratory depression, vs. 2% on placebo.<sup>1</sup></h1>",
                    "image": "program/demo1_assets/Chart3.png"
                },
                {
                    "content": "<p>Many medications, including alcohol, other analgesics or anesthetics, tranquilizers and sedatives, or other CNS depressants can potentiate the effects of Brandogesic®, resulting in respiratory or circulatory collapse, coma or death.<p>In the presence of closed head injury, the hypercapnic effects of Brandogesic® may elevate intracranial pressure.<p>Brandogesic® may exacerbate gastrointestinal obstruction, particularly in the setting of ileus.<p>Brandogesic® is not recommended for women who are or may become pregnant, during labor and delivery, or while nursing.<p>Patients should not perform activities such as driving a car or operating machinery until they understand the effects of Brandogesic® on mental and physical abilities.<p>Adverse reactions reported at (≥5%) in placebo-controlled trials were:<ul><li>sedation and somnolence or insomnia<li>nausea and/or vomiting<li>constipation or diarrhea<li>dizziness<li>pruritus<li>headache</ul>",
                    "image": ""
                },
                {
                    "content": "<p><sup>1</sup>2-year, randomized, double-blind, placebo-controlled study in 201 patients with Paroxysmal nocturnal hemoglobulinuria (PNH).  <i>N</i>= 201 patients.<p><sup>2</sup>Sedation and somnolence or insomnia: 13% (<i>N</i>= 201 <i>P</i>= 0.0050) vs. 4% on placebo Nausea and/or vomiting: 7% vs. 6% on placebo Constipation or diarrhea:  5% vs. 5% on placebo Priuritus:  5% vs. 4% on placebo Headace:  5% vs. 8% on placebo",
                    "image": ""
                }
				],
            "audio_url": "",
            "audio_autoplay": ""
			},
			{
				"id": "page3",
				"template": "Content",
				"title": "PeerPlay: Barndogesic",
				"headline": "Meaningful Efficacy Across Multiple Endpoints",
				"header": "Meaningful Efficacy Across Multiple Endpoints",
				"listcontent": [
					{
						"content": "<h1>A unique mechanism of action<sup>1</sup></h1>",
						"enlarge-image": "program/demo1_assets/Chart4.gif"
					},
					{
						"content": "<p>Brandogesic works by binding to CD55 and inhibits hemolysis specifically under conditions where blood CO<sub>2</sub> exceeds 25mEq/L,<sup>1</sup> controlling hemolysis only when blood nitrates are low and symptoms thought to be most evident.<sup>2</sup> CO<sub>2</sub> levels are thought to be higher during the day than at night, adding a further level of control.<sup>3,4</sup></p>",
						 "enlarge-image": ""
					},
					{
						"content": "<div><p><sup>1</sup>Derk AJ, Rado CF, Pugnisans EA <i>AJ Gen Mut</i> 2014;367:1020-1036.  Data on file.<p><sup>2</sup>Cicsea M et al. <i>Geneticiae</i> 2014;12:2030-2031 and n.<p><sup>3</sup>Matakishi ZR et al. <i>Sleep</i> 2009;1:20-41.",
						"image": ""
					}
				],
            "audio_url": "",
            "audio_autoplay": ""
			},
			{
				"id": "finalstep",
				"template": "Finalstep",
				"title": "Play Again",
				"headline": "Meaningful Efficacy Across Multiple Endpoints",
				"header": "Play Again",
				"content": "<p>Lorem ipsum dolor sit amet, consectetur adipisicing elit. Ducimus, excepturi, vero, quidem nisi inventore odit totam quos earum facere iure veritatis magnam nobis necessitatibus voluptates quibusdam recusandae quaerat facilis. Debitis.</p>"
			}
		]
	}
		
		